Autopsy report · NCT05362474

Targeting Leukotrienes in Kidney Disease

“Funding not available”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 year before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 1 year 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

University of Colorado, Denver

Sponsor type

University, hospital or other

Conditions

Diabetic Kidney Disease

Interventions

Montelukast

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
  “Funding was not available” (95% match in meaning)
• Optical Coherence Tomography in Staging Patients With Upper Tract Urothelial Cancer
  “Funding unavailable” (95% match in meaning)
• Evaluation and Adverse Event Surveillance for Initial Implementation of ShangRing Circumcision in Mozambique
  “Funding no longer available” (92% match in meaning)
• Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
  “Funding has become unavailable” (92% match in meaning)
• A Cardiac Registry to Evaluate and Manage the hsTnI Categorical CVD Risk in Subjects Undergoing Preventive Health Checks (PHC).
  “Unavailable funding” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.